![]() "Patients with symptomatic PAD are already at a heightened risk of hospitalization following revascularization," said lead study author Mark Svet, MD, internal medicine resident, University of Colorado Anschutz School of Medicine, in a statement. "Previously reported primary data from the VOYAGER PAD clinical trial established the benefit of Xarelto plus aspirin in patients with PAD. ![]() These findings, presented at the American College of Cardiology's (ACC) 71st Annual Scientific Session, highlight the impact of the rivaroxaban vascular dose in patients with PAD both with and without chronic kidney disease (CKD) and among those with and without a history of statin therapy, according to the study investigators. ![]() Data from the phase 3 VOYAGER PAD clinical trial found that rivaroxaban (Xarelto Janssen Pharmaceutical Companies) at a vascular dose of 2.5 mg twice daily plus aspirin 100 mg once daily lowers severe vascular events in patients with peripheral arterial disease (PAD) following lower-extremity revascularization (LER).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |